You are here: Industry Insights > Pharma in China > Chinese-produced New Drugs Approved for Marketing in 2018

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Chinese-produced New Drugs Approved for Marketing in 2018

PharmaSources/caicaiJanuary 21, 2019

Tag: New Drugs , Approved , 2018 , Chinese-produced Drugs

Favorites

Chinese-produced New Drugs Approved for Marketing in 2018:

Chinese-produced New Drugs Approved for Marketing in 2018

(Source: NMPA website, company announcements)

Pharmaceutical product name	Trade name	Registration classification	Company	Approval date	Indication
Recombinant Cytokine Gene Derived Protein Injection	Novaferon	Biological product for treatment 1	Genova Inc.	Apr. 20, 2018	HBV
Anlotinib Hydrochloride Capsules	FOCUS V	Chemical drug 1	Chiatai Tianqing	May 17, 2018	Locally advanced or metastatic NSCLC
Mecapegfilgrastim Injection	Aiduo	Biological product for treatment 9	Hengrui Medicine	May 17, 2018	Neutropenia
Albuvirtide for Injection	Aikening	Chemical drug 1	Frontier Biotechnologies	May 30, 2018	HIV-1
Danoprevir Sodium Tablets	Ganovo	Chemical drug 1	Ascletis	June 15, 2018	HCV
Pegylated Recombinant Interferon Variant Injection	Kailiwei	Biological product for treatment 9	Beijing Kawin	July 6, 2018	HCV
Pyrotinib Maleate Tablets	Airuini	Chemical drug 1	Hengrui Medicine	Aug. 17, 2018	Human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer
Fruquintinib Capsules	Elunate	Chemical drug 1	Hutchison MediPharma	Sep. 13, 2018	Colorectal cancer
Toripalimab Injection	Tuoyi	Biological product for treatment 1	Junshi Biosciences	Dec. 21, 2018	Melanoma
Sintilimab Injection	Tyvyt	Biological product for treatment 1	Innovent	Dec. 27, 2018	Classical Hodgkin's lymphoma
Jinrong Xiaopi Granules	/	TCM 6.1	Kangyuan Pharmaceutical	Dec. 27, 2018	Cyclomastopathy: intermingled phlegm and blood stasis and disharmony of the thoroughfare and conception vessels

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Chinese-produced new drugs to be marketed soon in 2019

Next:A Review of the Chinese-produced New Drugs Marketed in 2018

Joining Forces with Zai Lab: What is the Remaining Market Potential for Opdivo in China?

YefenghongMarch 06, 2024

Bristol Myers Squibb (BMS) recently announced the transfer of sales rights for one of its core products, the PD-1 monoclonal antibody Opdivo (nivolumab), in select provinces within China to the local biotechnology firm Zai Lab Limited (ZLAB).

Pharmaceutical Business in China and Worldwide (August)(2023)

PharmaSourcesOctober 01, 2023

Drug Marketing in China and Worldwide (September)(2023)

PharmaSourcesOctober 01, 2023

Chinese-produced New Drugs Approved for Marketing in 2018 | Pharmasources.com

Pharmaceutical Business in China and Worldwide (October)(2023)

PharmaSourcesNovember 01, 2023

Pharmaceutical companies sign cooperation agreements with research laboratories to provide commercialization of drug products.

Chinese-produced New Drugs Approved for Marketing in 2018

Related News

Joining Forces with Zai Lab: What is the Remaining Market Potential for Opdivo in China?

Pharmaceutical Business in China and Worldwide (August)(2023)

Drug Marketing in China and Worldwide (September)(2023)

Pharmaceutical Business in China and Worldwide (October)(2023)

You may like